Goldman Sachs Upgrades Crinetics Pharmaceuticals, Inc. (CRNX) To Buy From Neutral

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) is among the 14 best booming stocks to buy right now. On January 12, Goldman Sachs analyst Richard Law upgraded the stock’s rating to Buy from Neutral, with a share price target of $67.

The adjustment followed promising results from a trial investigating the impact of atumelnant on congenital adrenal hyperplasia (CAH). The findings revealed a 67% reduction in A4 in Cohort 4, replicating the results in the first three cohorts. Moreover, about 7 in 8 participants maintained a reduction in androgen, despite cutting the glucocorticoid dosage to protocol levels.

In other news, Citizens analyst Jonathan Wolleben on January 8 slightly cut the firm’s price target on Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) to $105 from $108, while maintaining an earlier Outperform rating on the shares.

The analyst cited a survey by American endocrinologists that revealed ‘positive early experience’ with the company’s recently launched drug, Palsonify, to treat acromegaly. In a research note to investors, Law said that the survey supported the Q4 preliminary net product revenue of over $5 million that the company announced earlier in the week.

According to a report on TipRanks, Citizens expects Palsonify to continue exceeding expectations in 2026.

Overall, Wall Street analysts have a bullish outlook on the stock with a consensus Strong Buy rating with a one-year average share price target of $88.64, representing an upside potential of 60.14% as of the close on January 12.

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) is a biopharmaceutical company that develops treatments for rare endocrine diseases and endocrine-related tumors.

While we acknowledge the potential of CRNX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 14 Best S&P 500 Stocks to Buy Now and 11 Most Oversold S&P 500 Stocks Heading into 2026

Disclosure: None.